| pubmed-article:10096509 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10096509 | lifeskim:mentions | umls-concept:C0031268 | lld:lifeskim |
| pubmed-article:10096509 | lifeskim:mentions | umls-concept:C0023688 | lld:lifeskim |
| pubmed-article:10096509 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:10096509 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:10096509 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:10096509 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10096509 | pubmed:dateCreated | 1999-8-2 | lld:pubmed |
| pubmed-article:10096509 | pubmed:abstractText | (+/-)-3-[11C]Methyl-2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-6 -methoxy-4(3H) quinazolinone ([+/-]-[11C]HX-CH 44) was labeled with carbon-11 using [11C]iodomethane with the corresponding N-demethylated precursor. Then, 30-90 mCi (1.10-3.33 GBq) of pure [11C]HX-CH 44 were obtained 30 min after end of bombardment with specific radioactivities of 500-1,400 mCi/micromol (18.5-51.8 GBq/micromol). Myocardial uptake in dogs was 0.340+/-0.043 pmol/mL tissue per nanomole injected, 10-15 min postinjection. Heart-to-lung ratio was 3 from the 5th to the 30th minute. Only 35% of the myocardial radioactivity could be displaced. Tissue uptake could not be blocked with appropriate compounds. Therefore, (+/-)-[11C]HX-CH 44 does not appear to be a suitable ligand for the study of myocardial beta1-adrenoceptors in positron emission tomography. | lld:pubmed |
| pubmed-article:10096509 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10096509 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10096509 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10096509 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:10096509 | pubmed:issn | 0969-8051 | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:ValetteHH | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:CrouzelCC | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:RasettiCC | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:FuseauCC | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:GuentherII | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:DolléFF | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:HinnenFF | lld:pubmed |
| pubmed-article:10096509 | pubmed:author | pubmed-author:DemphelSS | lld:pubmed |
| pubmed-article:10096509 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10096509 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:10096509 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10096509 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10096509 | pubmed:pagination | 105-9 | lld:pubmed |
| pubmed-article:10096509 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:meshHeading | pubmed-meshheading:10096509... | lld:pubmed |
| pubmed-article:10096509 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10096509 | pubmed:articleTitle | Preliminary evaluation of 2-[4-[3-tert-butylamino)-2-hydroxypropoxy]phenyl]-3-methyl-6-me thoxy-4(3H)-quinazolinone ([+/-]HX-CH 44) as a selective beta1-adrenoceptor ligand for PET. | lld:pubmed |
| pubmed-article:10096509 | pubmed:affiliation | Department de Recherche Medicale, Service Hospitalier Frederic Joliot, Orsay, France. | lld:pubmed |
| pubmed-article:10096509 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10096509 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
